New innovation in the field of diabetes and it's complications – new targets and findings in China and global.
Are you ready?
- Diabetes & it’s complications
- Global and China Diabetes EPI and key medicine sales
- Global and Chinese Top 10 endocrine TA players
- Global innovation pipeline in Endocrine TA
Event details
|
DATE Thursday,May 14, 2020 VENUE Online Webex / Gotomeeting TIME 9am -10am (Berlin time) | 3:00 PM - 4:00 PM (Beijing time) RSVP This is a complimentary event VIP tckets priority for Lingmed current clients Please RSVP by May 10, 2020 |
PRESENTERS Lingling Cao, CEO & Founder Dr Hank Wang, Medical advisor REGISTER +86 21 5386 3003 info@lingmed.net |
Agenda
| CET 9am - 9:10am | Linkedbio services & projects introductions | by LingLing Cao |
| CET 9:10 - 9:55 | New innovation in the field of diabetes and it's complications – new targets and findings in China and global. | by Dr Hank Wang |
| CET 9:55 - 10:00 | Q&A |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |